Press release
Acral Lentiginous Melanoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Adenoid Cystic Carcinoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Adenoid Cystic Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Adenoid Cystic Carcinoma Pipeline Report
* In May 2025, OncoC4 Inc. announced a Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
* DelveInsight's Adenoid Cystic Carcinoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Adenoid Cystic Carcinoma treatment.
* The leading Adenoid Cystic Carcinoma Companies such as Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co. and others.
* Promising Adenoid Cystic Carcinoma Pipeline Therapies such as CB-103, Abemaciclib, Lenvatinib, Enfortumab Vedotin, 177Lu-PNT2002, Pembrolizumab, AL101, Regorafenib, Dovitinib (TKI258) and others.
Stay ahead with the most recent pipeline outlook for Adenoid Cystic Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Adenoid Cystic Carcinoma Treatment Drugs [https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Adenoid Cystic Carcinoma Emerging Drugs Profile
* Rivoceranib : Elevar Therapeutics
Rivoceranib is the first small-molecule tyrosine kinase inhibitor to be approved in gastric cancer under the name Apatinib in China (December 2014). Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), the primary pathway for tumor angiogenesis. VEGFR-2 inhibition is a clinically validated approach to limit tumor growth and disease progression. Rivoceranib has been studied in over 1,000 patients worldwide and was well tolerated in clinical trials with a comparable safety profile to other TKIs. Rivoceranib is currently being studied as a monotherapy and in combination with chemotherapy and immunotherapy. Clinical studies are underway in multiple tumor types including, gastric cancer, hepatocellular carcinoma (combo w/camrelizumab), adenoid cystic carcinoma, and colorectal cancer (combo w/Lonsurf Registered ). Orphan drug designations for rivoceranib have been granted in gastric cancer (U.S., EU, and South Korea) in adenoid cystic carcinoma (U.S.), and hepatocellular carcinoma (U.S.).
* Osugacestat: Ayala Pharmaceuticals
Ayala Pharmaceuticals investigational lead candidate (AL-101) is a novel, injectable, potent and selective small molecule gamma secretase inhibitor (GSI). AL101 is currently being studied in 2 ongoing Phase 2 trials. The ACCURACY trial for the treatment of patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC), and our Phase 2 TENACITY trial for the treatment of patients with recurrent/metastatic triple negative breast cancer (R/M TNBC). The US Food and Drug Administration (FDA) granted Orphan Drug Designation and Fast Track Designation to AL101 for the potential treatment of ACC.
The Adenoid Cystic Carcinoma Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Adenoid Cystic Carcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adenoid Cystic Carcinoma Treatment.
* Adenoid Cystic Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Adenoid Cystic Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adenoid Cystic Carcinoma market
Explore groundbreaking therapies and clinical trials in the Adenoid Cystic Carcinoma Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Adenoid Cystic Carcinoma Drugs [https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Adenoid Cystic Carcinoma Companies
Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co. and others.
Adenoid Cystic Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Adenoid Cystic Carcinoma Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of Adenoid Cystic Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Adenoid Cystic Carcinoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Adenoid Cystic Carcinoma Pipeline Report
* Coverage- Global
* Adenoid Cystic Carcinoma Companies- Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co. and others.
* Adenoid Cystic Carcinoma Pipeline Therapies- CB-103, Abemaciclib, Lenvatinib, Enfortumab Vedotin, 177Lu-PNT2002, Pembrolizumab, AL101, Regorafenib, Dovitinib (TKI258) and others.
* Adenoid Cystic Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Adenoid Cystic Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Adenoid Cystic Carcinoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Adenoid Cystic Carcinoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Adenoid Cystic Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Adenoid Cystic Carcinoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* AL101: Ayala Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Adenoid Cystic Carcinoma Key Companies
* Adenoid Cystic Carcinoma Key Products
* Adenoid Cystic Carcinoma- Unmet Needs
* Adenoid Cystic Carcinoma- Market Drivers and Barriers
* Adenoid Cystic Carcinoma- Future Perspectives and Conclusion
* Adenoid Cystic Carcinoma Analyst Views
* Adenoid Cystic Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acral-lentiginous-melanoma-pipeline-appears-robust-with-5-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/adenoid-cystic-carcinoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acral Lentiginous Melanoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4047719 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Adenoid
Adenoid Cystic Carcinoma Pipeline Outlook 2025: Insights Into Therapies, Researc …
DelveInsight's, "Adenoid Cystic Carcinoma Pipeline Insight 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenoid Cystic Carcinoma pipeline landscape. It covers the Adenoid Cystic Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adenoid Cystic Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…
Adenoid Cystic Carcinoma Market Outlook, Trends, Challenges and Growth Potential
Adenoid Cystic Carcinoma (ACC) is a rare and slow-growing cancer that typically arises in the salivary glands but can also occur in the breast, trachea, lacrimal glands, and other sites. While it progresses more slowly than many other malignancies, ACC is highly invasive and has a tendency to recur and metastasize even after years of remission. Due to its rarity and complexity, treatment options remain limited, primarily revolving around surgery…
Adenoid cystic carcinoma Market Outlook 2034 - Clinical Trials, Market Size, Med …
Adenoid cystic carcinoma companies are OncoC4, Ascentage Pharma, Elevar Therapeutics, CELLESTIA BIOTECH AG, Remix Therapeutics, Rgenta Therapeutics Inc and others.
(Albany, USA) DelveInsight's "Adenoid cystic carcinoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Adenoid cystic carcinoma, historical and forecasted epidemiology as well as the Adenoid cystic carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Adenoid cystic carcinoma…
Adenoid Cystic Carcinoma Market Scope and Competitive Analysis Forecast through …
The Adenoid Cystic Carcinoma Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/adenoid-cystic-carcinoma-market
What is the…
Revolutionizing Respiratory Health: Unveiling the Latest Breakthroughs in Adenoi …
DelveInsight's, "Adenoid Cystic Carcinoma Pipeline Insight 2023," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Adenoid Cystic Carcinoma pipeline landscape. It covers the Adenoid Cystic Carcinoma pipeline drug profiles, including Adenoid Cystic Carcinoma clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Tonsil and Adenoid Removal Products Market Forecast to 2022
The objective of this report is to describe the market trends and revenue forecasts for tonsil and adenoid removal products market for the next five years. The report focuses on defining and describing the key influencing factors for the growth of the market. It also offers an in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, key market players, and premium industry trends.
The report…
